全文获取类型
收费全文 | 1830篇 |
免费 | 131篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 65篇 |
妇产科学 | 23篇 |
基础医学 | 183篇 |
口腔科学 | 44篇 |
临床医学 | 228篇 |
内科学 | 410篇 |
皮肤病学 | 25篇 |
神经病学 | 85篇 |
特种医学 | 271篇 |
外科学 | 149篇 |
综合类 | 45篇 |
一般理论 | 3篇 |
预防医学 | 153篇 |
眼科学 | 59篇 |
药学 | 102篇 |
中国医学 | 8篇 |
肿瘤学 | 110篇 |
出版年
2024年 | 2篇 |
2023年 | 24篇 |
2022年 | 32篇 |
2021年 | 63篇 |
2020年 | 45篇 |
2019年 | 75篇 |
2018年 | 103篇 |
2017年 | 44篇 |
2016年 | 51篇 |
2015年 | 54篇 |
2014年 | 79篇 |
2013年 | 86篇 |
2012年 | 108篇 |
2011年 | 112篇 |
2010年 | 67篇 |
2009年 | 83篇 |
2008年 | 60篇 |
2007年 | 40篇 |
2006年 | 48篇 |
2005年 | 32篇 |
2004年 | 22篇 |
2003年 | 42篇 |
2002年 | 31篇 |
2001年 | 21篇 |
2000年 | 11篇 |
1999年 | 16篇 |
1998年 | 50篇 |
1997年 | 54篇 |
1996年 | 67篇 |
1995年 | 50篇 |
1994年 | 43篇 |
1993年 | 48篇 |
1992年 | 15篇 |
1991年 | 7篇 |
1990年 | 14篇 |
1989年 | 34篇 |
1988年 | 32篇 |
1987年 | 32篇 |
1986年 | 33篇 |
1985年 | 23篇 |
1984年 | 15篇 |
1983年 | 11篇 |
1982年 | 22篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1977年 | 13篇 |
1976年 | 11篇 |
1975年 | 13篇 |
排序方式: 共有1971条查询结果,搜索用时 15 毫秒
1.
Moncef Khairallah Padmamalini Mahendradas Andre Curi Sana Khochtali Emmett T. Cunningham Jr. 《Ocular immunology and inflammation》2019,27(2):219-228
Purpose: To review the systemic and ocular manifestations of specific emergent viral infectious diseases relevant to the ophthalmologist with particular emphasis on anterior uveitisMethods: Review of literature.Results: Arboviral diseases are among the most important emergent and resurgent human infections, occurring mostly in tropical and subtropical zones, but appearing in virtually all regions of the world as a result of climate change, travel, and globalization. Arboviral infections are transmitted to humans by the bite of hematophagous arthropods, mainly mosquitoes. Systemic disease may range from asymptomatic to life-threatening. A wide variety of ocular manifestations, including uveitis, has been reported in association with these emerging viral diseases. Numerous viruses other than arboviruses also have been recently recognized as a potential cause of uveitis.Conclusions: Proper clinical diagnosis of any emerging infectious disease is based on epidemiological data, history, systemic symptoms and signs, and the pattern of ocular involvement. The diagnosis is usually confirmed by detection of virus-specific DNA or antivirus antibodies in serum. 相似文献
2.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.